AbbVie Inc. (ABBV)

86.66
0.22 0.25
NYSE : Health Technology
Prev Close 86.44
Open 85.74
Day Low/High 85.33 / 87.27
52 Wk Low/High 62.66 / 94.98
Volume 5.85M
Avg Volume 7.93M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 126.68B
EPS 3.70
P/E Ratio 37.57
Div & Yield 4.72 (5.02%)
Betting on U.S. Economy Muddling Along

Betting on U.S. Economy Muddling Along

I like cheap smaller caps with little to no exposure to the global economy.

AbbVie's Triangle Chart Formation Is Pointed South

AbbVie's Triangle Chart Formation Is Pointed South

A breakdown below $52 should be the tipping point for further declines in ABBV. 

Biotech Rally Is Healing Small-Caps

Biotech Rally Is Healing Small-Caps

This sector is finally bouncing from deeply oversold levels.

My Takeaways and Observations

If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...

Silly Season Continues for Biotech

Silly Season Continues for Biotech

Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.

My Takeaways and Observations

I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here.  Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...

Trump or Hillary? These Stocks Don't Care Who Wins

Trump or Hillary? These Stocks Don't Care Who Wins

Some names should do well regardless of who becomes the next president.

Political Headwinds Hit the Market: Part 2

Political Headwinds Hit the Market: Part 2

Some stocks should do well regardless of who is the next president.

Abbvie upgraded at Citi

I'm Mr. Brightside

I'm Mr. Brightside

I am not ready to go full "risk on," but it's nice to see the market out of its cage.

Bright Idea: Redeploy Some Utility Gains

Bright Idea: Redeploy Some Utility Gains

The electrics have been crackling, but the group has more downside risk than currently perceived.

Play Strong Defense With 3 Big Biotechs

Play Strong Defense With 3 Big Biotechs

They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.

Stocks Continue to Sink

The market's major indices are getting worse as the morning progresses. There are deep losses across the board, with the Nasdaq Composite down nearly 3% at last check. Maybe we'll get some relief from the European markets closing. Oil is holding its...

Stocking Up on Cheap Biotech Stocks

Stocking Up on Cheap Biotech Stocks

In a year's time, investors may look back and think this was a great entry point.

What to Watch When 3 Big Biotechs Report

What to Watch When 3 Big Biotechs Report

Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

3 Things the Market Needs to Get Off the Mat

3 Things the Market Needs to Get Off the Mat

The year has not started the way most pundits and prognosticators had envisioned.

3 Scorned Biotechs Destined to Rebound

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.

3 Scorned Biotechs Destined to Rebound

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.

Cheap Big-Cap Stocks That I Like for 2016

Cheap Big-Cap Stocks That I Like for 2016

It was all about the FANGs in 2015, but go for value plays this year.

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.

2016 Outlook: FANGs Bite as Value Plays Gain

2016 Outlook: FANGs Bite as Value Plays Gain

Look for market leadership to shift as the U.S. economy plods along.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.

Avoid These Investment Mistakes in 2016

Avoid These Investment Mistakes in 2016

Don't catch falling knives, and don't ignore dividends.

3 Biotech Stocks to Buy into 2016

3 Biotech Stocks to Buy into 2016

GILD, CELG and ABBV will lead the biotech resurgence.

AstraZeneca to Pay $4 Billion for 55 Percent of Acerta Pharma

AstraZeneca to Pay $4 Billion for 55 Percent of Acerta Pharma

United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.

Cramer: Dow Chemical-DuPont Merger Will Instantly Create Value

Cramer: Dow Chemical-DuPont Merger Will Instantly Create Value

The merged company can become multiple companies.

6 Dowdy Drug Stocks to Consider for 2016

6 Dowdy Drug Stocks to Consider for 2016

History indicates pharmaceutical companies with low multiples offer payoffs down the road.

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Don't Abandon the Biotech Ship

Don't Abandon the Biotech Ship

There's too much good out there.